B. Braun Medical has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its Introcan Safety 2 deep access IV catheter.
 
The new catheter merges the technologies of the original Introcan Safety 2 multi-access and Introcan Safety deep access catheter. The company said the resulting solution combines the strengths of both devices.
 
Introcan Safety 2 deep access offers automatic passive safety needlestick protection and multi-access blood control in longer lengths. This was designed, according to B. Braun, to access deeper veins in patients with difficult vascular access, and to achieve longer dwell times.
 
The new catheter was demonstrated to increase PIVC catheter dwell times to about 5.7 days, compared to 3.8 days for standard long PIVCs. This helps reduce PIVC restarts and minimize escalation to more costly, invasive devices line peripherally inserted central catheters (PICC).
 
The multi-access blood control hub aims to minimize blood exposure and reduce the need for blood cleanup through IV therapy. There’s also not a need to occlude the vessel during insertion or any time the hub is accessed, the company said.
 
“We are excited to broaden our Introcan Safety 2 IV Catheter portfolio, allowing our customers to benefit from passive safety and blood exposure protection with deep access technology,” said Chad Laity, B. Braun Medical Inc.’s Director of Marketing, Vascular Access, IV Systems and Securement. “By offering a reliable solution for challenging cases, we aim to help improve patient outcomes and reduce the need for more complex procedures.”